N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US10647717B2 · kind B2 · utility
0Cited by
3References
3Claims
0Family size
Assignees
Inventors
- Rhalid Akkari
- Luke Jonathan Alvey
- Xavier Marie Bock
- Brian S. Brown
- Pieter Isabelle Roger Claes
- Marlon D. Cowart
- Elsa De Lemos
- Nicolas Desroy
- Béranger Duthion
- Gregory A. Gfesser
- Romain Luc Marie Gosmini
- Christopher Gaëtan Housseman
- Koen Karel Jansen
- Jianguo Ji
- Philip R. Kym
- Jean-Michel Lefrancois
- Oscar Mammoliti
- Christel Jeanne Marie Menet
- Nuria Merayo Merayo
- Gregory John Robert Newsome
- Adeline Marie Elise Palisse
- Sachin V. Patel
- Matthieu Rafaël Pizzonero
- Anurupa Shrestha
- Elizabeth C. Swift
- Steven Emiel Van der Plas
- Xueqing Wang
- Ann de Blieck
Key dates
| Filing date | Jun 18, 2019 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Jun 18, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.